2025年医药健康盘点2025年,中国医药健康领域迎来从“量变”到“质变”的关键跃升,是政策、技术与产业协同成效。治疗端,GLP-1类药物从“奢侈品”走向平民化,脑机接口技术突破瘫痪与抑郁治疗瓶颈,阿尔茨海默病药物的沉浮折射研发理性回归,集采“反内卷”重构行业竞争逻辑,“医保+商保”双目录机制破解高值药支付困局;创新端,AI制药打破研发“不可能三角”,创新药以千亿美元级交易实现全球领跑。八大关键词...
Source Link2025年医药健康盘点2025年,中国医药健康领域迎来从“量变”到“质变”的关键跃升,是政策、技术与产业协同成效。治疗端,GLP-1类药物从“奢侈品”走向平民化,脑机接口技术突破瘫痪与抑郁治疗瓶颈,阿尔茨海默病药物的沉浮折射研发理性回归,集采“反内卷”重构行业竞争逻辑,“医保+商保”双目录机制破解高值药支付困局;创新端,AI制药打破研发“不可能三角”,创新药以千亿美元级交易实现全球领跑。八大关键词...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.